An AstraZeneca spokesperson stated that their vaccine candidate, AZD1222, includes the genetic material of the SARS-CoV-2 virus spike protein, and the recent changes in the genetic code of the new viral strain do not seem to alter the structure of the spike protein. Drug manufacturers are rushing to test their COVID-19 vaccines against the highly contagious new variant of the virus spreading rapidly in Britain, presenting a new challenge in the race to control the pandemic. By administering AZD1222, the immune system is taught to recognize various parts of the spike protein, enabling it to eliminate the virus upon exposure. The mutation, known as the B.1.1.7 lineage, is thought to be up to 70% more transmissible and poses a greater risk for children. This has caused disruption in Britain, leading to travel bans that are impacting trade with Europe and potentially isolating the island nation further. The AstraZeneca-Oxford vaccine is viewed as essential for poorer nations and countries with hot climates due to its affordability, ease of transportation, and ability to be stored at regular refrigerator temperatures for extended periods. Results from AstraZeneca's trials in the UK and Brazil indicated a 62% efficacy rate for participants who received two full doses, but a 90% efficacy rate for a smaller group who received a half dose followed by a full dose. India is expected to approve the emergency use of AstraZeneca's vaccine by next week, according to Reuters.